SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals receives USFDA’s approvals for ANDAs

22 Nov 2019 Evaluate

Alembic Pharmaceuticals has received approvals from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs). The USFDA has given final approvals for Deferasirox Tablets 90 mg & 360 mg, Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, & 500 mg, and tentative approval for Deferasirox Tablets 180 mg.

Alembic now has a total of 107 ANDA approvals (95 final approvals and 12 tentative approvals) from USFDA. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

815.20 -12.35 (-1.49%)
02-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.55
Dr. Reddys Labs. 1346.25
Cipla 1456.25
Zydus Lifesciences 1099.65
Lupin 2398.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: